주식/증권
📈 긍정적
Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck’s Keytruda
요약
A late-stage trial evaluating Regeneron’s fianlimab, a skin cancer drug, fails to meet its primary endpoint.